Aliases & Classifications for Vulvar Disease

MalaCards integrated aliases for Vulvar Disease:

Name: Vulvar Disease 12 15
Vulvar Diseases 44 70
Vulvar Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:2059
MeSH 44 D014845
NCIt 50 C27631
SNOMED-CT 67 5089007
UMLS 70 C0042994

Summaries for Vulvar Disease

MedlinePlus : 42 The vulva is the external part of a woman's genitals. Some problems you can have with the vulvar area include Vaginitis or vulvovaginitis, swelling or infection of the vulva and vagina Skin problems due to allergy Vulvar cancer Vulvodynia, or vulvar pain Symptoms may include redness, itching, pain, or cracks in the skin. Treatment depends on the cause.

MalaCards based summary : Vulvar Disease, also known as vulvar diseases, is related to atrophic vulva and vulvar dystrophy, and has symptoms including pelvic pain and pruritus vulvae. An important gene associated with Vulvar Disease is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Acetylcholine and Neurotransmitter Agents have been mentioned in the context of this disorder. Affiliated tissues include vulva, skin and lymph node, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A female reproductive system disease that is located in the vulva.

Wikipedia : 73 A vulvar disease is a particular abnormal, pathological condition that affects part or all of the vulva.... more...

Related Diseases for Vulvar Disease

Diseases related to Vulvar Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 639)
# Related Disease Score Top Affiliating Genes
1 atrophic vulva 32.1 KRT7 CDKN2A
2 vulvar dystrophy 31.5 TP53 KRT13 CDKN2A CD34
3 vulvar intraepithelial neoplasia 30.9 TP53 CDKN2A
4 human papillomavirus infectious disease 30.3 TP53 KRT13 CDKN2A
5 cervix uteri carcinoma in situ 30.2 TP53 GP5 CDKN2A
6 squamous cell papilloma 30.1 TP53 HRAS GP5 CDKN2A
7 keratosis 30.0 TP53 PIK3CA HRAS CDKN2A
8 mammary paget's disease 30.0 PIP KRT7 ERBB2 EGFR
9 keratosis, seborrheic 29.8 TP53 PIK3CA KRT7 CEACAM5 CDKN2A
10 anogenital venereal wart 29.8 TP53 GP5 CDKN2A CD4
11 vulva squamous cell carcinoma 29.4 TP53 PIK3CA MIR3147 GP5 EGFR CDKN2A
12 hemangioma 29.3 TP53 PTEN KRT7 KIT CD34
13 in situ carcinoma 29.1 TP53 PTEN PIP PIK3CA HRAS ERBB2
14 exanthem 29.0 KIT HRAS ERBB2 EGFR CD4 CD274
15 squamous cell carcinoma 28.7 TP53 PTEN PIK3CA KRT7 HRAS ERBB2
16 papilloma 28.4 TP53 PTEN KRT7 KRT13 ERBB2 EGFR
17 vulva cancer 27.1 TP53 PTEN PIP PIK3CA MIR3147 MIR223
18 vulvitis 11.0
19 ulceration of vulva 10.9
20 cervical basaloid squamous cell carcinoma 10.5 KRT7 CDKN2A
21 inverted transitional papilloma 10.5 KRT7 CDKN2A
22 gastric signet ring cell adenocarcinoma 10.4 PIP KRT7
23 ceruminoma 10.4 PIP KRT7
24 trachea carcinoma in situ 10.4 HRAS CDKN2A
25 pancreatic signet ring cell adenocarcinoma 10.4 TP53 HRAS
26 bartholin's gland disease 10.4 PIP KRT7
27 leukoplakia of penis 10.4 KRT7 CEACAM5
28 mucoepidermoid esophageal carcinoma 10.4 TP53 CEACAM5
29 bartholin's gland carcinoma 10.4 PIP KRT7
30 malignant peritoneal mesothelioma 10.4 EGFR CDKN2A
31 laryngeal small cell carcinoma 10.4 KIT CDKN2A
32 anus basaloid carcinoma 10.4 PIK3CA KRT7
33 urethral villous adenoma 10.4 KRT7 CEACAM5
34 ovarian seromucinous carcinoma 10.4 TP53 KRT7 CDKN2A
35 ureter adenocarcinoma 10.4 KRT7 CEACAM5
36 mucinous adenofibroma 10.4 KRT7 CEACAM5
37 anal canal paget's disease 10.4 PIP KRT7 CDKN2A
38 bladder clear cell adenocarcinoma 10.4 TP53 KRT7 CDKN2A
39 cervical adenoid cystic carcinoma 10.4 KRT7 KIT CDKN2A
40 benign breast adenomyoepithelioma 10.4 KRT7 EGFR
41 necrotizing sialometaplasia 10.4 TP53 KRT7
42 bile duct adenoma 10.4 TP53 KRT7 CDKN2A
43 gastric papillary adenocarcinoma 10.4 TP53 ERBB2
44 eyelid carcinoma 10.4 PIP KRT7
45 adult teratoma 10.4 TP53 CEACAM5
46 fox-fordyce disease 10.4 PIP CEACAM5
47 esophageal basaloid squamous cell carcinoma 10.4 TP53 EGFR
48 signet ring basal cell carcinoma 10.4 HRAS CEACAM5
49 epstein-barr virus-associated gastric carcinoma 10.4 CDKN2A CD274
50 pancreatic serous cystadenocarcinoma 10.4 KRT7 CEACAM5

Graphical network of the top 20 diseases related to Vulvar Disease:



Diseases related to Vulvar Disease

Symptoms & Phenotypes for Vulvar Disease

UMLS symptoms related to Vulvar Disease:


pelvic pain; pruritus vulvae

GenomeRNAi Phenotypes related to Vulvar Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.66 EGFR HRAS PIK3CA
2 Decreased viability GR00055-A-2 9.66 EGFR HRAS PIK3CA
3 Decreased viability GR00221-A-1 9.66 CDKN2A EGFR HRAS KIT NRAS PIK3CA
4 Decreased viability GR00221-A-2 9.66 HRAS PIK3CA
5 Decreased viability GR00221-A-3 9.66 CDKN2A HRAS NRAS
6 Decreased viability GR00221-A-4 9.66 CDKN2A EGFR PIK3CA
7 Decreased viability GR00301-A 9.66 KIT
8 Decreased viability GR00402-S-2 9.66 PIK3CA

MGI Mouse Phenotypes related to Vulvar Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 CD274 CD34 CD4 CDKN2A EGFR ERBB2
2 homeostasis/metabolism MP:0005376 10.28 CD274 CD34 CD4 CDKN2A EGFR ERBB2
3 digestive/alimentary MP:0005381 10.22 CD4 CDKN2A EGFR ERBB2 HRAS KIT
4 endocrine/exocrine gland MP:0005379 10.2 CD4 CDKN2A EGFR ERBB2 HRAS KIT
5 integument MP:0010771 10.18 CD274 CD34 CD4 CDKN2A EGFR ERBB2
6 neoplasm MP:0002006 10.02 CD34 CDKN2A EGFR ERBB2 HRAS KIT
7 muscle MP:0005369 9.97 CDKN2A EGFR ERBB2 HRAS KIT PIK3CA
8 no phenotypic analysis MP:0003012 9.91 CD274 CD4 CDKN2A EGFR HRAS KIT
9 normal MP:0002873 9.81 CD4 EGFR ERBB2 GP5 HRAS KIT
10 pigmentation MP:0001186 9.43 CDKN2A EGFR KIT NRAS PTEN TP53
11 skeleton MP:0005390 9.32 CD274 CDKN2A EGFR ERBB2 HRAS KIT

Drugs & Therapeutics for Vulvar Disease

Drugs for Vulvar Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2 Neurotransmitter Agents Phase 4
3 abobotulinumtoxinA Phase 4
4 Cholinergic Agents Phase 4
5 Botulinum Toxins Phase 4
6 Botulinum Toxins, Type A Phase 4
7
Nifedipine Approved Phase 3 21829-25-4 4485
8 Vasodilator Agents Phase 3
9 Tocolytic Agents Phase 3
10 Hormones Phase 3
11 calcium channel blockers Phase 3
12 Calcium, Dietary Phase 3
13
Calcium Nutraceutical Phase 3 7440-70-2 271
14
Capsaicin Approved Phase 1, Phase 2 404-86-4 1548943
15
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
16
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
17
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
18 Dermatologic Agents Phase 1, Phase 2
19 Antirheumatic Agents Phase 1, Phase 2
20 Immunosuppressive Agents Phase 1, Phase 2
21 Immunologic Factors Phase 1, Phase 2
22 Alkylating Agents Phase 1, Phase 2
23 Anti-Retroviral Agents Phase 1, Phase 2
24 Antiviral Agents Phase 1, Phase 2
25 Anti-HIV Agents Phase 1, Phase 2
26 Vaccines Phase 1, Phase 2
27 Anti-Infective Agents Phase 1, Phase 2
28
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
29
Methylene blue Approved, Investigational Phase 1 61-73-4
30
Ropivacaine Approved Phase 1 84057-95-4 71273 175805
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
32
Artesunate Approved, Investigational Phase 1 88495-63-0 5464098 6917864
33 Antimalarials Phase 1
34 Antiparasitic Agents Phase 1
35 Anthelmintics Phase 1
36 Antiprotozoal Agents Phase 1
37
Lidocaine Approved, Vet_approved 137-58-6 3676
38
Desipramine Approved, Investigational 50-47-5 2995
39 Anti-Arrhythmia Agents
40 Psychotropic Drugs
41 Sodium Channel Blockers
42 Antidepressive Agents
43 Diuretics, Potassium Sparing
44 Adrenergic Agents
45 Antidepressive Agents, Tricyclic
46 Anesthetics
47 Anesthetics, Local

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Botox on Vulvar Vestibulitis Unknown status NCT00119886 Phase 4 Botulinum toxin
2 Topical Application of Nifedipine Cream for the Treatment of Vulvar Vestibulitis Syndrome Completed NCT00496184 Phase 3 Nifedipine cream topical application
3 Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis Completed NCT00004316 Phase 1, Phase 2 capsaicin
4 A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 With or Without PD-1 Blockade for HPV-Associated Cancers Recruiting NCT02858310 Phase 1, Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
5 Evaluation of the Efficacy of Mixed Methylene Blue Compound Injection for the Treatment of Nonneoplastic Epithelial Disorders of Vulva. Unknown status NCT03200808 Phase 1 mixed methylene blue compound injection
6 A Phase I Proof-of-Concept Study of Artesunate Ointment for the Treatment of Patients With High-Grade Vulvar Intraepithelial Neoplasia (HSIL VIN 2/3) Recruiting NCT03792516 Phase 1 artesunate ointment 40%
7 Vulvar Vestibulitis Trial: Desipramine-Lidocaine Completed NCT00276068 topical lidocaine + oral desipramine, and/or placebo
8 Treatment Prior to Injection and Biopsy of the Vulva Recruiting NCT03444727
9 Effectiveness and Cost-utility of Somatocognitive Therapy Versus Treatment as Usual for Provoked (Localized) Vestibulodynia - a Randomized Clinical Trial (ProLoVe Study) Recruiting NCT04613713
10 Open Ended Chart Review of Adult Women Presenting to the Vulvar Mucosal Specialty Clinic at Northwestern University Department of Dermatology Terminated NCT02881229

Search NIH Clinical Center for Vulvar Disease

Cochrane evidence based reviews: vulvar diseases

Genetic Tests for Vulvar Disease

Anatomical Context for Vulvar Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Vulvar Disease:

19
Vulva

MalaCards organs/tissues related to Vulvar Disease:

40
Skin, Lymph Node, Breast, Cervix

Publications for Vulvar Disease

Articles related to Vulvar Disease:

(show top 50) (show all 235)
# Title Authors PMID Year
1
PHOTODYNAMIC THERAPY IN TREATMENT OF PATIENTS WITH PREMALIGNANT VULVAR DISEASES. FIRST EXPERIENCE OF THE METHOD APPLICATION IN UKRAINE. 42 61
33526722 2020
2
Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007-2018). 42
33208109 2020
3
A Systematic Review of Nonsurgical Vulvovaginal Restoration Devices: An Evidence-Based Examination of Safety and Efficacy. 42
33141529 2020
4
Four-decade trends in lymph node status of patients with vulvar squamous cell carcinoma in northern Italy. 61
33707570 2021
5
[Interdisciplinary S2k guidelines on the diagnosis and treatment of vaginal carcinoma and its precursors-recommendations on surgical pathology for histopathological workup, diagnostics, and reporting]. 61
33346872 2021
6
Cancer-related cognitive impairment (CRCI), depression and quality of life in gynecological cancer patients: a prospective study. 61
33404703 2021
7
Association Between Vulvar Squamous Intraepithelial Lesions and Psychiatric Illness. 61
33181537 2021
8
The prevalence of self-reported medical comorbidities in patients with vulvar lichen sclerosus: A single-center retrospective study. 61
33184843 2020
9
Pictorial Representation of Illness and Self-Measure to assess the perceived burden in patients with chronic inflammatory vulvar diseases: an observational study. 61
32597539 2020
10
Diagnosis and Management of Vulvovaginal Lichen Planus. 61
33111963 2020
11
A Qualitative Exploration of Women's Experiences of Living With Chronic Vulvar Dermatoses. 61
32741746 2020
12
A randomized clinical study of the treatment of white lesions of the vulva with a fractional ultrapulsed CO2 laser. 61
32762229 2020
13
Vulvar diseases: Conditions in adults and children. 61
31712170 2020
14
Comparison of Serum Vitamin D Levels in Relation to Bowel and Bladder Symptoms in Women with Vulvar Diseases. 61
30747611 2020
15
Vulvar diseases: Approach to the patient. 61
31712174 2020
16
Concordance rate of vulvoscopic findings in detecting early vulvar neoplasia. 61
32107046 2020
17
Vulvar quality of life index (VQLI) - A simple tool to measure quality of life in patients with vulvar disease. 61
31984477 2020
18
Perception of Labial Size and Objective Measurements-Is There a Correlation? A Cross-Sectional Study in a Cohort Not Seeking Labiaplasty. 61
31918983 2020
19
Pediatric and Young Adult Vulvovaginal Graft-versus-Host Disease. 61
31325588 2019
20
Successful pregnancy and delivery following selective use of photodynamic therapy in treatment of cervix and vulvar diseases. 61
31299392 2019
21
Clinical and epidemiological profile of patients attended in a vulvar clinic of the dermatology outpatient unit of a tertiary hospital during a 4-year period. 61
30892698 2019
22
No. 385-Indications for Pelvic Examination. 61
31331610 2019
23
Basal cell carcinoma of the vulva: a case report and systematic review of the literature. 61
30506682 2019
24
[Inflammatory Diseases of the Vulva - a Dermatologist's Point of View]. 61
31822232 2019
25
"The Future of Vulvar Disease: New and Ongoing Challenges": Presidential Lecture - XXIV World Congress 2017, Mendoza, Argentina. 61
29474239 2018
26
Generalized unprovoked vulvodynia; A retrospective study on the efficacy of treatment with amitriptyline, gabapentin or pregabalin. 61
29202395 2018
27
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. 61
28886907 2017
28
HPV-related vulvar diseases and perspectives of p16INK4a immunochemistry: a review of the literature. 61
28574130 2017
29
Evaluation and Management of Vulvar Disease. 61
28778648 2017
30
High-Yield Vulvar Histopathology for the Clinician. 61
28778634 2017
31
Red Rashes of the Vulva. 61
28778636 2017
32
Risk factors for unrecognized invasive carcinoma in patients with vulvar high-grade squamous intraepithelial lesion at vulvoscopy-directed biopsy. 61
28541626 2017
33
HPV status and favourable outcome in vulvar squamous cancer. 61
27864932 2017
34
Lichenoid vulvar disease: A review. 61
28492056 2017
35
Vulvar Cancer in China: Epidemiological Features and Risk Analysis. 61
28928886 2017
36
What Do Patients Want? A Needs Assessment of Vulvodynia Patients Attending a Vulvar Diseases Clinic. 61
27484917 2016
37
Extra Mammary Paget's Disease of Vulva-a Case Report. 61
27872543 2016
38
Primary extramammary invasive Paget's vulvar disease: what is the standard, what are the challenges and what is the future for radiotherapy? 61
27473174 2016
39
Level of use and safety of botanical products for itching vulvar dermatoses. Are patch tests useful? 61
26928795 2016
40
Pelvic floor symptoms in female cyclists and possible remedies: a narrative review. 61
26239955 2016
41
Surgical management of vulvovaginal agglutination due to lichen planus. 61
26348378 2016
42
Epithelioid sarcoma of the vulva and its clinical implication: A case report and review of the literature. 61
26937486 2016
43
Sexual well-being in patients with vulvar disease: results from a preliminary prospective matched case-control study. 61
26342683 2015
44
Psychosexual Aspects of Vulvar Disease. 61
26125964 2015
45
Lower Urinary Tract and Functional Bowel Symptoms in Women With Vulvar Diseases and Controls. 61
26052645 2015
46
History of Abuse in Women With Vulvar Pruritus, Vulvodynia, and Asymptomatic Controls. 61
26111040 2015
47
Ultrasound-guided high intensity focused ultrasound for the treatment of gynaecological diseases: A review of safety and efficacy. 61
25609456 2015
48
Vulvar cancer: a review for dermatologists. 61
25930015 2015
49
[VULVAR INTRAEPITHELIAL NEOPLASIA--TERMINOLOGY, SYMPTOMS AND TREATMENT]. 61
27025107 2015
50
[Vulvar diseases]. 61
25475624 2015

Variations for Vulvar Disease

Expression for Vulvar Disease

Search GEO for disease gene expression data for Vulvar Disease.

Pathways for Vulvar Disease

Pathways related to Vulvar Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 TP53 PTEN PIK3CA NRAS KIT HRAS
2
Show member pathways
13.9 TP53 PTEN PIP NRAS KIT HRAS
3
Show member pathways
13.61 TP53 PIK3CA NRAS KIT HRAS ERBB2
4
Show member pathways
13.57 PIK3CA NRAS KRT7 KRT13 KIT HRAS
5
Show member pathways
13.48 TP53 PTEN PIK3CA NRAS KIT HRAS
6
Show member pathways
13.47 TP53 PTEN PIP NRAS KIT HRAS
7
Show member pathways
13.43 TP53 PIK3CA NRAS KIT HRAS ERBB2
8
Show member pathways
13.37 PTEN PIP NRAS KIT HRAS ERBB2
9
Show member pathways
13.18 TP53 PTEN PIK3CA KIT ERBB2 EGFR
10
Show member pathways
13.15 TP53 PTEN PIK3CA NRAS HRAS EGFR
11
Show member pathways
13.13 TP53 PTEN NRAS KIT HRAS EGFR
12
Show member pathways
13.07 TP53 PTEN PIK3CA NRAS KIT HRAS
13
Show member pathways
13.01 TP53 PIK3CA NRAS HRAS EGFR CDKN2A
14
Show member pathways
12.98 PTEN PIK3CA NRAS HRAS ERBB2 EGFR
15
Show member pathways
12.97 PTEN PIK3CA NRAS HRAS ERBB2 EGFR
16
Show member pathways
12.94 PTEN PIK3CA NRAS HRAS ERBB2 EGFR
17
Show member pathways
12.9 PIK3CA NRAS KIT HRAS EGFR
18 12.84 TP53 NRAS KIT HRAS ERBB2 EGFR
19
Show member pathways
12.8 PIK3CA NRAS KIT HRAS EGFR
20
Show member pathways
12.8 TP53 PTEN PIK3CA NRAS HRAS ERBB2
21
Show member pathways
12.8 TP53 PTEN PIK3CA NRAS KIT HRAS
22
Show member pathways
12.78 TP53 PIK3CA NRAS HRAS CDKN2A
23 12.75 TP53 PTEN PIK3CA NRAS KIT HRAS
24
Show member pathways
12.74 PIK3CA NRAS KRT13 HRAS EGFR
25
Show member pathways
12.74 TP53 NRAS HRAS EGFR CD4
26
Show member pathways
12.74 TP53 PTEN PIK3CA NRAS KIT HRAS
27
Show member pathways
12.69 TP53 PTEN PIK3CA NRAS HRAS ERBB2
28
Show member pathways
12.68 TP53 PTEN PIK3CA NRAS HRAS ERBB2
29
Show member pathways
12.67 PTEN PIK3CA NRAS HRAS EGFR CD4
30
Show member pathways
12.65 TP53 PIK3CA NRAS HRAS ERBB2 EGFR
31
Show member pathways
12.64 TP53 PTEN PIK3CA NRAS KIT HRAS
32
Show member pathways
12.6 TP53 PTEN PIK3CA NRAS HRAS EGFR
33
Show member pathways
12.56 PTEN PIK3CA NRAS HRAS ERBB2
34
Show member pathways
12.55 TP53 PIK3CA NRAS HRAS ERBB2 EGFR
35
Show member pathways
12.54 TP53 PTEN PIK3CA NRAS HRAS ERBB2
36
Show member pathways
12.53 PTEN PIK3CA NRAS HRAS CD4
37
Show member pathways
12.49 PIK3CA NRAS KIT HRAS EGFR
38
Show member pathways
12.48 PIK3CA NRAS KIT HRAS ERBB2 EGFR
39
Show member pathways
12.46 PTEN PIK3CA NRAS HRAS
40
Show member pathways
12.45 TP53 PTEN PIK3CA HRAS
41
Show member pathways
12.43 PIK3CA NRAS HRAS ERBB2 EGFR
42
Show member pathways
12.41 TP53 PTEN PIK3CA HRAS ERBB2 EGFR
43
Show member pathways
12.39 PIK3CA HRAS ERBB2 EGFR
44 12.39 TP53 PIK3CA NRAS HRAS CDKN2A
45 12.39 TP53 PIK3CA NRAS HRAS ERBB2 EGFR
46
Show member pathways
12.37 TP53 NRAS HRAS EGFR
47
Show member pathways
12.37 PIK3CA NRAS HRAS ERBB2 EGFR
48 12.32 TP53 PTEN PIK3CA NRAS HRAS CDKN2A
49
Show member pathways
12.3 PIK3CA NRAS HRAS CEACAM5
50
Show member pathways
12.3 TP53 PTEN PIK3CA NRAS HRAS ERBB2

GO Terms for Vulvar Disease

Cellular components related to Vulvar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.73 PIK3CA MIR223 HRAS ERBB2 EGFR CD34
2 apical plasma membrane GO:0016324 9.35 PTEN ERBB2 EGFR CEACAM5 CD34
3 basal plasma membrane GO:0009925 9.33 ERBB2 EGFR CD34
4 cell surface GO:0009986 9.1 KIT EGFR CEACAM5 CD4 CD34 CD274

Biological processes related to Vulvar Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.88 HRAS ERBB2 EGFR CD4 CD274
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 PTEN HRAS EGFR CD4
3 positive regulation of protein phosphorylation GO:0001934 9.85 HRAS ERBB2 EGFR CD4
4 positive regulation of protein kinase B signaling GO:0051897 9.83 PIK3CA KIT ERBB2 EGFR
5 MAPK cascade GO:0000165 9.77 NRAS KIT HRAS ERBB2 EGFR
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.73 KIT ERBB2 EGFR CD4
7 positive regulation of epithelial cell proliferation GO:0050679 9.71 HRAS ERBB2 EGFR
8 positive regulation of MAPK cascade GO:0043410 9.71 KIT HRAS ERBB2 CD4
9 phosphatidylinositol 3-kinase signaling GO:0014065 9.63 PTEN PIK3CA ERBB2
10 tongue development GO:0043586 9.58 KIT EGFR
11 somatic stem cell division GO:0048103 9.58 KIT CDKN2A
12 enzyme linked receptor protein signaling pathway GO:0007167 9.56 ERBB2 CD4
13 positive regulation of kinase activity GO:0033674 9.56 KIT ERBB2 EGFR CD4
14 negative regulation of ERBB signaling pathway GO:1901185 9.51 ERBB2 EGFR
15 ERBB2 signaling pathway GO:0038128 9.5 PIK3CA ERBB2 EGFR
16 negative regulation of immature T cell proliferation in thymus GO:0033088 9.49 ERBB2 CDKN2A
17 Ras protein signal transduction GO:0007265 9.46 TP53 NRAS HRAS CDKN2A
18 positive regulation of gene expression GO:0010628 9.28 TP53 PTEN PIP MIR223 KIT HRAS
19 positive regulation of MAP kinase activity GO:0043406 9.26 KIT HRAS ERBB2 EGFR

Molecular functions related to Vulvar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 TP53 PTEN EGFR CDKN2A CD4
2 MDM2/MDM4 family protein binding GO:0097371 8.96 TP53 CDKN2A
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 KIT ERBB2 EGFR

Sources for Vulvar Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....